BiotechTube
Acumen Pharmaceuticals

Acumen Pharmaceuticals

ABOS
United States
acumenpharm.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

ABOS · Stock Price

USD 2.47+1.49 (+152.04%)
Market Cap: $179.1M

Historical price data

Overview

Acumen Pharmaceuticals is a public, clinical-stage biotech singularly focused on developing targeted Alzheimer's disease therapies based on the amyloid-beta oligomer (AβO) hypothesis. Its lead candidate, sabirnetug (ACU193), is a first-in-class monoclonal antibody in Phase 2 development, designed for high selectivity to soluble AβOs. The company has built a seasoned leadership team with deep Alzheimer's expertise, secured foundational IP from leading academic institutions, and is advancing a subcutaneous formulation and an Enhanced Brain Delivery platform. With Phase 2 enrollment complete, Acumen is positioned to generate critical efficacy data that could validate its differentiated scientific approach.

Alzheimer's DiseaseNeurodegenerative Diseases

Technology Platform

Platform focused on selectively targeting toxic soluble amyloid-beta oligomers (AβOs) via monoclonal antibodies, with an adjunct Enhanced Brain Delivery (EBD™) platform to increase CNS exposure.

Pipeline

3
3 drugs in pipeline
DrugIndicationStageWatch
sabirnetug + PlaceboAlzheimer DiseasePhase 2
ACU193 + PlaceboAlzheimer DiseasePhase 1
sabirnetug (ACU193)Alzheimer DiseasePhase 1

Funding History

3
Total raised:$260M
IPO$160M
Series B$60M
Series A$40M

Opportunities

A successful Phase 2 trial for sabirnetug could validate the AβO hypothesis and position it as a best-in-class therapy with a potentially superior safety profile, capturing significant market share in the multi-billion dollar Alzheimer's market.
Development of a subcutaneous formulation offers a major convenience advantage that could expand treatment access.

Risk Factors

High clinical risk that the Phase 2 trial fails to demonstrate efficacy, which would challenge the company's core scientific premise.
Financial risk is acute, with limited cash runway extending just past the expected trial readout, making the company dependent on positive data to secure future funding.

Competitive Landscape

Competes directly with approved plaque-clearing antibodies (lecanemab, aducanumab) and next-generation candidates like donanemab. Differentiation hinges on sabirnetug's selective AβO targeting potentially yielding better efficacy and/or a significantly improved safety profile (lower ARIA incidence) to gain market traction.

More companies in United States →